Hans T. Scambye joins Sunstone as Venture Partner

by | Jan 28, 2025

Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025.

With a background as an MD and PhD Hans brings to Sunstone over 25 years of experience within corporate strategy, drug discovery and development and financing of biotech companies.

Prior to co-founding Galecto, Hans served as the CEO of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company acquired by Maxygen in 2000. Hans has also served on a number of biotech company boards, including Step Pharma and IO Biotech (both in our portfolio), as well as Forward Pharma, which secured a +billion USD deal with Biogen. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Molecular Pharmacology from Copenhagen University.

Besides his positions as Galecto CEO and member of BioInnovation Institute’s Board, Hans is the Chairman of the Board of Danish Bio, working tirelessly to promote innovation, research and development in life science in Denmark.

As Venture Partner, Hans will participate in qualifying our deal flow and providing supportive feedback to entrepreneurs that reach out to Sunstone. He will complement Sunstone’s other three part-time Venture Partners to help ensure Sunstone maintains access to a broader set of competencies and experiences.

We look forward to welcoming Hans and we are confident that his extensive experience will greatly benefit Sunstone.